Zentalis Pharmaceuticals, Inc. Common Stock (ZNTL) is a publicly traded Healthcare sector company. As of May 21, 2026, ZNTL trades at $3.80 with a market cap of $258.41M and a P/E ratio of -1.92. ZNTL moved +4.52% today. Year to date, ZNTL is +170.80%; over the trailing twelve months it is +189.84%. Its 52-week range spans $1.01 to $6.95. Analyst consensus is buy with an average price target of $7.00. Rallies surfaces ZNTL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
ZNTL financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. ZNTL recently traded at $3.80. Market cap is $258.41M. P/E ratio is -1.92. Revenue is $0.
| Metric | Value |
|---|---|
| Price | $3.80 |
| Market Cap | $258.41M |
| P/E Ratio | -1.92 |
| EPS | $-1.91 |
| Dividend Yield | 0.00% |
| 52-Week High | $6.95 |
| 52-Week Low | $1.01 |
| Volume | 52 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-137.06M |
| Gross Margin | 0.00% |
| Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2024 | $67.42M | $-165.87M | $-2.33 |
| 2023 | $0 | $-292.31M | $-4.47 |
| 2022 | $0 | $-237.11M | $-4.48 |
| 2021 | $0 | $-166.09M | $-3.78 |
7 analysts cover ZNTL: 0 strong buy, 4 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $7.00.